Clinical Trial Update: Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) [Phase 4]

View source ↗

Summary

This update reports an extension of the MAGNIFY MS trial for Mavenclad in multiple sclerosis, with Phase 4 results posted in January 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2025-01-22